Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we will assume that you are happy to receive all cookies and you will not see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

The scheme is a collaboration between Oxford University, the global drug discovery company Evotec, and the investment fund Oxford Sciences Innovation (OSI).

Deborah GoberdhanIn partnership with Evotec, a drug discovery company, Associate Professor Deborah Goberdhan has received a LAB282 award of half a million pounds to screen for inhibitors of proteins that selectively promote cancer growth. 

This award builds on over fifteen years of work, initiated and undertaken in Oxford, on the amino acid regulation of the growth-regulating kinase complex mTORC1 by so-called ‘transceptors’, proteins that look like transporters, but actually sense amino acids.

Prof Goberdhan commented: "We have taken this work forward translationally with an outstanding group of clinical collaborators in Oxford, facilitated by the Cancer Research UK Oxford Centre. We have also identified other putative regulators of cancer growth and progression, which we plan to develop in a similar way."